Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease

被引:5
|
作者
Shi, Yichao [1 ,2 ]
Li, Jianfeng [2 ]
Cai, Shuntian [2 ]
Zhao, Hong [3 ]
Zhao, Huijun [2 ]
Sun, Gang [2 ]
Yang, Yunsheng [2 ,4 ]
机构
[1] Peking Univ, Aerosp Ctr Hosp, Dept Gastroenterol, Aerosp Sch Clin Med, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gastroenterol & Hepatol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
关键词
gastroesophageal reflux disease; proton pump inhibitor; fecal mycobiota; Candida; gastric mucosal mycobiota; LONG-TERM USE; CANDIDA-ALBICANS; COMMENSAL FUNGI; THERAPY; MICROBIOME; RISK; INFLAMMATION; PROPHYLAXIS; MEDICATION; ESOPHAGUS;
D O I
10.3389/fcimb.2023.1205348
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gut mycobiota inhabits human gastrointestinal lumen and plays a role in human health and disease. We investigated the influence of proton pump inhibitors (PPIs) on gastric mucosal and fecal mycobiota in patients with gastroesophageal reflux diseases (GERD) by using Internal Transcribed Spacer 1 sequencing. A total of 65 participants were included, consisting of the healthy control (HC) group, GERD patients who did not use PPIs (nt-GERD), and GERD patients who used PPIs, which were further divided into short-term (s-PPI) and long-term PPI user (l-PPI) groups based on the duration of PPI use. The alpha diversity and beta diversity of gastric mucosal mycobiota in GERD patients with PPI use were significantly different from HCs, but there were no differences between s-PPI and l-PPI groups. LEfSe analysis identified Candida at the genus level as a biomarker for the s-PPI group when compared to the nt-GERD group. Meanwhile, Candida, Nothojafnea, Rhizodermea, Ambispora, and Saccharicola were more abundant in the l-PPI group than in the nt-GERD group. Furthermore, colonization of Candida in gastric mucosa was significantly increased after PPI treatment. However, there was no significant difference in Candida colonization between patients with endoscopic esophageal mucosal breaks and those without. There were significant differences in the fecal mycobiota composition between HCs and GERD patients regardless whether or not they used PPI. As compared to nt-GERD patient samples, there was a high abundance of Alternaria, Aspergillus, Mycenella, Exserohilum, and Clitopilus in the s-PPI group. In addition, there was a significantly higher abundance of Alternaria, Aspergillus, Podospora, Phallus, and Monographella in the l-PPI group than nt-GERD patients. In conclusion, our study indicates that dysbiosis of mycobiota was presented in GERD patients in both gastric mucosal and fecal mycobiota. PPI treatment may increase the colonization of Candida in the gastric mucosa in GERD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [22] Endoscopic management of gastroesophageal reflux disease: Panacea for proton pump inhibitors dependent/refractory patients
    Kalapala, Rakesh
    Singla, Neeraj
    Reddy, Duvvur Nageshwar
    DIGESTIVE ENDOSCOPY, 2022, 34 (04) : 687 - 699
  • [23] Factors Associated With Persistent Use of Proton Pump Inhibitors Among Patients With Gastroesophageal Reflux Disease
    Rane, Pratik P.
    Guha, Sushovan
    Aparasu, Rajender
    GASTROENTEROLOGY, 2016, 150 (04) : S240 - S240
  • [24] Proton Pump Inhibitors Improve Acid-Related Dyspepsia in Gastroesophageal Reflux Disease Patients
    Motoyasu Kusano
    Yasuyuki Shimoyama
    Osamu Kawamura
    Masaki Maeda
    Shikou Kuribayashi
    Atsuto Nagoshi
    Hiroaki Zai
    Fumitaka Moki
    Tsutomu Horikoshi
    Munetoshi Toki
    Sayaka Sugimoto
    Masatomo Mori
    Digestive Diseases and Sciences, 2007, 52 : 1673 - 1677
  • [25] Consumer Use of Over-the-Counter Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease
    Sheikh, Imran
    Waghray, Abhijeet
    Waghray, Nisheet
    Dong, Chunrong
    Wolfe, M. Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (06): : 789 - 794
  • [26] Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients
    Grigolon, Ausilia
    Cantu, Paolo
    Savojardo, Daniela
    Conte, Dario
    Penagini, Roberto
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (09) : 969 - 973
  • [27] Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients
    Kusano, Motoyasu
    Shimoyama, Yasuyuki
    Kawamura, Osamu
    Maeda, Masaki
    Kuribayashi, Shikou
    Nagoshi, Atsuto
    Zai, Hiroaki
    Moki, Fumitaka
    Horikoshi, Tsutomu
    Toki, Munetoshi
    Sugimoto, Sayaka
    Mori, Masatomo
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (07) : 1673 - 1677
  • [28] WILLINGNESS TO STOP PROTON PUMP INHIBITORS IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE: RESULTS OF A PATIENT SURVEY
    Kennedy, Jennifer K.
    Saini, Sameer
    Kurlander, Jacob E.
    GASTROENTEROLOGY, 2018, 154 (06) : S887 - S887
  • [29] Histology of symptomatic gastroesophageal reflux disease: Is it predictive of response to proton pump inhibitors?
    Miwa, Hiroto
    Takubo, Kaiyo
    Shimatani, Tomohiko
    Furuta, Takahisa
    Oshima, Tadayuki
    Tanaka, Junji
    Aida, Junko
    Ito, Masanori
    Kurosawa, Susumu
    Joh, Takashi
    Wada, Tsuneya
    Habu, Yasuki
    Watanabe, Yusuke
    Hongo, Michio
    Chiba, Tsutomu
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (03) : 479 - 487
  • [30] Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
    Kierkus, Jaroslaw
    Oracz, Grzegorz
    Korczowski, Bartosz
    Szymanska, Edyta
    Wiernicka, Anna
    Woynarowski, Marek
    DRUG SAFETY, 2014, 37 (05) : 309 - 316